Maxim Group Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $0.75
Maxim Group Initiates Coverage On Avenue Therapeutics With Buy Rating, Announces Price Target of $0.75
Maxim集團以買入評級啓動對Avenue Therapeutics的報道,宣佈目標股價爲0.75美元
Maxim Group analyst Jason McCarthy initiates coverage on Avenue Therapeutics (NASDAQ:ATXI) with a Buy rating and announces Price Target of $0.75.
Maxim集團分析師傑森·麥卡錫以買入評級開始對Avenue Therapeutics(納斯達克股票代碼:ATXI)進行報道,並宣佈目標股價爲0.75美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。